Abstract
Vessel calcification involves an active cellular process. However, the events by which calcification occurs in vascular endothelial cells have not been sufficiently studied. We performed experiments that evaluated the effect of osteogenic medium (OM) on alkaline phosphatase activity, signaling pathways and cell death in human umbilical vein endothelial cells (HUVEC). We found that OM emits a survival signal at the beginning of cell culture and then causes massive cell death. The formation of intracellular calcium accumulation led to complete calcification spread by alkaline phosphatase produced in stimulated cells. To better understand the signaling networks involved, we analyzed the HUVEC- and HUVEC-treated cell lysates using the Kinexus™ KPSS 1.3 phospho-site pathway screen. Our studies revealed that STAT3 Serine 727 phosphorylation is enhanced in HUVEC. Treatment with 5-aza-2-deoxycytidine led up to inhibition of calcium accumulation induced by OM. These data suggest that under calcifying conditions, STAT3 is a potential important mediator of calcium uptake in endothelial cells. Continuing research is revealing the similarities, differences and deficiencies of STAT3 activities in diverse processes including the calcification of vessels.
Keywords: Vascular calcification, STAT3, Alkaline Phosphatase, 5-aza-2'-deoxycytidine, autophagy
Current Chemical Biology
Title: Enhanced Activity of pSTAT-3 Ser-727 in Functional Endothelial Cells Under Calcifying Conditions
Volume: 4 Issue: 2
Author(s): Jorge Flavio Mendoza-Rincon, Arturo Gonzalez-Robles, Rebeca Lopez-Marure and Julio Roberto Caceres-Cortes
Affiliation:
Keywords: Vascular calcification, STAT3, Alkaline Phosphatase, 5-aza-2'-deoxycytidine, autophagy
Abstract: Vessel calcification involves an active cellular process. However, the events by which calcification occurs in vascular endothelial cells have not been sufficiently studied. We performed experiments that evaluated the effect of osteogenic medium (OM) on alkaline phosphatase activity, signaling pathways and cell death in human umbilical vein endothelial cells (HUVEC). We found that OM emits a survival signal at the beginning of cell culture and then causes massive cell death. The formation of intracellular calcium accumulation led to complete calcification spread by alkaline phosphatase produced in stimulated cells. To better understand the signaling networks involved, we analyzed the HUVEC- and HUVEC-treated cell lysates using the Kinexus™ KPSS 1.3 phospho-site pathway screen. Our studies revealed that STAT3 Serine 727 phosphorylation is enhanced in HUVEC. Treatment with 5-aza-2-deoxycytidine led up to inhibition of calcium accumulation induced by OM. These data suggest that under calcifying conditions, STAT3 is a potential important mediator of calcium uptake in endothelial cells. Continuing research is revealing the similarities, differences and deficiencies of STAT3 activities in diverse processes including the calcification of vessels.
Export Options
About this article
Cite this article as:
Flavio Mendoza-Rincon Jorge, Gonzalez-Robles Arturo, Lopez-Marure Rebeca and Roberto Caceres-Cortes Julio, Enhanced Activity of pSTAT-3 Ser-727 in Functional Endothelial Cells Under Calcifying Conditions, Current Chemical Biology 2010; 4 (2) . https://dx.doi.org/10.2174/2212796811004020133
DOI https://dx.doi.org/10.2174/2212796811004020133 |
Print ISSN 2212-7968 |
Publisher Name Bentham Science Publisher |
Online ISSN 1872-3136 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeted Therapy for Advanced Renal Cell Cancer: Cytokines and Beyond
Current Pharmaceutical Design Antibacterial and Antitumorigenic Properties of Microcin E492, a Pore- Forming Bacteriocin
Current Pharmaceutical Biotechnology Epigenetic Targeting of Platinum Resistant Testicular Cancer
Current Cancer Drug Targets Potential Impacts of Prebiotics and Probiotics on Cancer Prevention
Anti-Cancer Agents in Medicinal Chemistry Mitochondria and Organismal Longevity
Current Genomics Can the Use of HIV-1 Derived Gene Transfer Vectors for Clinical Application be Justified?
Current Gene Therapy Myocardial Infarction after Rituximab Treatment for Rheumatoid Arthritis: Is there a Link?
Current Pharmaceutical Design Treatment of HCV-Related Mixed Cryoglobulinemia
Current Drug Targets miRNAs Highlights in Stem and Cancer Cells
Mini-Reviews in Medicinal Chemistry Ibrutinib: A New Frontier in the Treatment of Chronic Lymphocytic Leukemia by Bruton’s Tyrosine Kinase Inhibition
Cardiovascular & Hematological Agents in Medicinal Chemistry Significance of 1,3,4-Oxadiazole Containing Compounds in New Drug Development
Current Drug Research Reviews Mitochondrial-Targeted Plastoquinone Derivatives. Effect on Senescence and Acute Age-Related Pathologies
Current Drug Targets Modulating Mitochondria-Mediated Apoptotic Cell Death through Targeting of Bcl-2 Family Proteins
Recent Patents on DNA & Gene Sequences Testicular Germ Cell Tumors: A Paradigm for the Successful Treatment of Solid Tumor Stem Cells
Current Cancer Therapy Reviews Strategies for the Biological Evaluation of Gold Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Targeted Protein Degradation: An Emerging Therapeutic Strategy in Cancer
Anti-Cancer Agents in Medicinal Chemistry Novel Genetic and Peptide-Based Strategies Targeting the Bcl-2 Family, an Update
Recent Patents on DNA & Gene Sequences Stem Cell Defects in Philadelphia Chromosome Negative Chronic Myeloproliferative Disorders: A Phenotypic and Molecular Puzzle?
Current Stem Cell Research & Therapy mTOR Inhibitors: Facing New Challenges Ahead
Current Medicinal Chemistry Editorial [Hot Topic: Novel and Emerging Drugs for Leukemias (Guest Editor: Tadeusz Robak)]
Current Cancer Drug Targets